Jefferies Raises BioMarin (BMRN) Stock Price Target on Settlement
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowJefferies has increased the stock price target for BioMarin Pharmaceuticals (BMRN) following the settlement related to Ascendis. This new target reflects an adjustment based on the settlement's implications for BioMarin’s market position and future earnings. The specific new price target was not mentioned in the article. This adjustment may influence investor sentiment and stock performance, making it relevant for current and potential shareholders in BioMarin.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
